CA-HYPERICE
15.9.2022 12:02:01 CEST | Business Wire | Press release
Hyperice, a global high-performance wellness brand, today announced two new products within their heat therapy category, Venom Go and Venom 2, alongside HyperHeat™ technology for the fastest, most consistent and even distribution of heat to relieve sore, stiff muscles and promote wellness. Venom Go advances the capabilities of the Venom line further with the ability to deliver heat and vibration spot treatment in more areas, such as the neck, shoulder, upper and lower back, calf and forearm. Designed with flexibility in mind, Venom Go can be utilized in more environments than ever before, with unmatched versatility and customizations, delivering instant muscle relief wherever the body needs it most. Venom 2 is the most advanced heat and massage wrap on the market and carries on the legacy built by the original Venom line, which revolutionized the traditional heating pad for consumers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220915005442/en/
"The new Venom Go allows me to be even more targeted with muscle recovery to keep me moving at my best so I can help others move at their best too.” -Robin Arzón, Hyperice Athlete-Investor, and Peloton Vice President of Fitness Programming. (Photo: Business Wire)
“The new Venom Go is a revolutionary product for us as it widens the application of our Venom technology and addresses the need for a powerful heat and vibration solution for spot treatment,” said Jim Huether, CEO of Hyperice. “It’s been six years since the debut of heat and vibration technology from Hyperice, we’ve now significantly enhanced the Venom user experience and added our patented HyperHeat™ technology, all while staying true to the core elements of the original product that made people fall in love with it. The Venom line is one of our fastest growing product lines, and we expect this trend to continue in the U.S. and throughout the world.”
INTRODUCING VENOM GO
The Venom Go is a heat and vibration wearable that consists of a control pod that magnetically connects to an adhesive pad and is applied directly to the skin. Venom Go pads are reusable approximately 20 to 40 times each (depending on placement on body and any sweat, lotion or oil that may be on the skin) and cover 13.5 square inches, allowing users to receive direct treatment to more areas of the body than ever before. Users can select from 3 levels of heat and 3 levels of vibration via easy to use button control on the pod. Sore and stiff muscles can now receive instant treatment, with Venom Go reaching up to 113℉ (45°C) in 90 seconds after applied to the skin - or just 20 seconds prior to being applied to the skin.
The Venom Go control pod and pad weighs a mere 0.2 lbs, and holds a battery life of up to 60 minutes on a full charge, with a standard session running for 10 minutes. The Venom Go is charged via USB connection and is TSA approved for convenient use while traveling. Utilizing Bluetooth connectivity, the Venom Go is controlled via the Hyperice App, with users having the ability to sync multiple pods to deliver tailored spot treatments across different areas of the body at once for a unique heat and vibration therapy experience.
“Recovery plays a key role in performing your best every day,” said Robin Arzón, Hyperice Athlete-Investor, and Peloton Vice President of Fitness Programming. “Venom has always been a staple product in my warmup and recovery routines. Vibration and heat are both critical components in the equation. The new Venom Go allows me to be even more targeted with muscle recovery to keep me moving at my best so I can help others move at their best too.”
The introduction of the Venom Go comes on the heels of the introduction of the Normatec Go (currently only available in the US), and now provides a holistic suite of products within Hyperice’s Go series (Hypersphere Mini, Hypervolt Go 2, Vyper Go, Normatec Go). Portable and mobile adaptations of each product line offer users maximum flexibility to experience the benefits of warm up and recovery technology in more places, and at more price points, than ever before.
“With the Venom Go, users will be able to experience the same benefits they have grown to know and love in the Venom line, but in many more targeted areas for relief,” added Huether. “This product is amazing for anyone with soreness, stiffness or pain in targeted areas, and furthers our mission to help as many people as possible improve their daily lives through recovery and movement.”
INTRODUCING VENOM 2
The Venom 2, which comes in versions for the back, leg and shoulder (left or right), has more-than-doubled its treatment area, increasing the overall heating surface by 111% (94 square inches), and is encased in a new silicone surface for easier cleaning. Venom 2 delivers up to a three-hour battery life on a full charge, and heats to 131℉ (55°C) in just one minute, which is four times faster than the original Venom, and six times faster than a traditional heating pad. Users will also experience a lighter version of the Venom, as the weight drops by more than 23% from the original version, now weighing just two lbs.
“Heat therapy is such a critical component of my routine, from preparing for a game and getting my shoulder loose, to treating sore muscles in my arm between practices,” said Patrick Mahomes, Hyperice Athlete-Investor and Super Bowl Champion. “From pregame, to the training facility and home, the Venom line allows me to optimize my performance. The new Venom 2 improves the experience and I know will be a popular tool in the locker room.”
“As a footballer, I need to ensure that my body is ready to endure the rigors that come with a 90-minute match,” said Erling Haaland, Hyperice Athlete-Investor and global footballer. “Heat therapy is very important in ensuring my body is properly prepared and ready to go ahead of training or kickoff, and equally important in the time between match-days. I’m always looking for ways to give myself a competitive edge, and with Venom 2’s heating time, I feel the benefits quicker than ever before, and can be ready to take the pitch faster with my body ready to go.”
Through Bluetooth® connectivity, the Venom 2 is controlled via the Hyperice App, unlocking more routines to maximize and customize time, heat and vibration while using the device.
HYPERHEAT™ TECHNOLOGY
With the launch of Venom Go and the Venom 2, Hyperice also introduces their new HyperHeat™ technology which delivers a faster, more consistent distribution of heat across a greater surface area, allowing for a more premium experience for users.
“In 2015 we were getting requests from NBA players for a product that could heat the body pregame and keep the body warm when they came out of the game. Our answer was the Venom, the first heat and vibration wearable device, released in 2017,” said Anthony Katz, Hyperice Founder. “Over the past five years, the user base for the Venom has expanded far beyond performance athletes to everyday people who use the Venom to manage pain and soreness. The Venom 2 is a complete redesign and upgrade from the original model- every aspect of the product and experience have been improved.“
The Venom Go ($149; £159; €175) and Venom 2 line ($249; £269; €299) are available in North America as well as globally across all countries and regions where Hyperice is sold. For more information, please visit hyperice.com country-specific sites.
About Hyperice
Hyperice is a technology-driven company with a giant mission, to help everyone on Earth move and live better. For more than a decade, Hyperice has led a global movement at the confluence of recovery and wellness, specializing in percussion (Hypervolt line), dynamic air compression (Normatec line), vibration (Vyper and Hypersphere lines), thermal technology (Venom line), mind technology (Core by Hyperice) and contrast therapy (Hyperice X). Now, as a holistic high-performance wellness brand, Hyperice is designed for all - from the most elite athletes, leagues and teams to consumers everywhere looking to unlock the best version of themselves to help them do what they love, more. Recognized as one of Fast Company’s Most Innovative Companies, Hyperice has applied its technology and know-how to industries including fitness, hospitality, healthcare, massage, physical therapy, sports performance and workplace wellness on a global scale. Hyperice’s transformative acquisitions of Normatec, RecoverX and Core have helped to accelerate its innovation agenda as it enters its next stage of global growth. For more information, visit the newly redesigned hyperice.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220915005442/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Imagine Dragons to Perform at Abu Dhabi Grand Prix21.5.2026 17:51:00 CEST | Press release
Ethara, organiser of the Formula 1 Etihad Airways Abu Dhabi Grand Prix, have announced that one of the world’s biggest bands, Imagine Dragons, will headline the Saturday After-Race Concerts at the F1 Season Finale in Abu Dhabi. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521214839/en/ Imagine Dragons to perform at Formula 1 Etihad Airways Abu Dhabi Grand Prix (Photo: AETOSWire) The announcement is another landmark moment for the Abu Dhabi Grand Prix, whose thrilling Yasalam presented by e& fan entertainment offering has become synonymous with the F1 Championship finale in Abu Dhabi and is recognised as one of the most compelling sports and entertainment crossovers globally. The global chart-toppers join Lewis Capaldi and Zara Larsson, who are set to kick off a blockbuster line-up of performances on Yas Island on Thursday, 3 December, with more major international artists to be revealed. With their popular top hits, Ima
Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 14:05:00 CEST | Press release
Trained on more than 13,000 patient studies, novel system significantly outperforms existing models by up to 35% A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is d
Otovo Hits 30,000 Customers in Under a Year, Tackling the Growing ‘Solar Service Crisis’21.5.2026 14:00:00 CEST | Press release
A growing wave of unsupported solar systems and rising electricity prices are creating strong demand for Otovo’s energy service platform Otovo ASA (“Otovo”), a leading global energy service provider for residential and commercial customers, today announced it has reached 30,000 customers across the U.S. and Europe. A total of 20,000 customers have enrolled in Otovo Care, the Company’s membership-based home and commercial energy service, which is powered by Otovo’s industry-leading AI platform, Endurance™. “Reaching 30,000 customers in less than year is proof positive that home and business owners value their power systems,” said William J. (John) Berger, CEO of Otovo. “The ‘solar service crisis’ that is leaving millions of orphaned energy systems without support is driving strong interest in our Otovo Care membership program. Every day your home or commercial power system is not working, you are throwing money away. Otovo’s rapid response service platform keeps you up and running, ensu
The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 14:00:00 CEST | Press release
New research shows that brands aligned with emotionally heightened moments in live sports can improve ad effectiveness Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The r
Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 14:00:00 CEST | Press release
Precemtabart tocentecan (Precem-TcT) is investigated as a potential first-in-class anti-CEACAM5 ADC, for the treatment of metastatic CRC (mCRC) CEACAM5 is overexpressed in the majority of colorectal tumors (~90%), and requires no patient selection Significant unmet need remains for clinically meaningful innovation in colorectal cancer (CRC), the second leading cause of cancer death worldwide Not intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
